1767-25-5

Basic information

• Product Name: 2-Phenyl-1H-benzoimidazol-5-ylamine
• Synonyms: 1H-BenziMidazol-6-aMine,2-phenyl-
• CAS NO: 1767-25-5
• Molecular Formula: C₁₃H₁₁N₃
• Molecular Weight: 209.25
• Mol File: 1767-25-5.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 474.8 °C at 760 mmHg
• Flash Point: 272.4 °C
• Appearance: /
• Density: 1.286 g/cm³
• Vapor Pressure: 3.5E-09mmHg at 25°C
• Refractive Index: 1.737
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: 2-Phenyl-1H-benzoimidazol-5-ylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Phenyl-1H-benzoimidazol-5-ylamine(1767-25-5)
• EPA Substance Registry System: 2-Phenyl-1H-benzoimidazol-5-ylamine(1767-25-5)

Safety Data

• Hazardous Substances Data: 1767-25-5(Hazardous Substances Data)

Usage

General Description

2-Phenyl-1H-benzo[de]isoquinoline-1,3(2H)-dione, more commonly known as 2-Phenyl-1H-benzoimidazol-5-ylamine, is a chemical compound with the molecular formula C20H14N2O2. It belongs to the class of organic compounds known as benzoimidazoles, which are organic compounds containing a benzene ring fused to an imidazole ring. Imidazole is a five-member ring that contains two nitrogen atoms and three carbon atoms. This specific chemical, 2-Phenyl-1H-benzoimidazol-5-ylamine, isn't well-studied, so its properties, uses, and impact on human health are largely unknown. As it is a complex organic compound, it commonly features in organic chemistry studies.

InChI:InChI=1/C13H11N3/c14-10-6-7-11-12(8-10)16-13(15-11)9-4-2-1-3-5-9/h1-8H,14H2,(H,15,16)

Upstream product

• 1571-85-3 6-nitro-2-phenyl-1H-benzo[d]imidazole 
• 716-79-0 2-phenyl-1H-benzoimidazole 
• 99-56-9 4-Nitrophenylene-1,2-diamine 
• 100-52-7 benzaldehyde 
• 56120-01-5 2',4'-diaminobenzanilide 
• 220641-69-0 N-(2-amino-5-nitrophenyl)benzamide 
• 65-85-0 benzoic acid 
• 4657-12-9 sodium hydroxy(phenyl)methanesulfonate 
• 97-02-9 2,4-Dinitroanilin 
• 98-88-4 benzoyl chloride 
• 41214-79-3 N-(2,4-dinitrophenyl)benzamide 
• 1571-85-3 2-phenyl-5-nitrobenzimidazole 

Downstream Products

• 84121-99-3 2-phenyl-1⁽³⁾H-imidazo[4,5-f]quinoline 
• 19250-69-2 N-(2-phenyl-1⁽³⁾H-benzoimidazol-5-yl)-benzamide 
• 300384-33-2 C₂₀H₁₄N₄O₃ 
• 1440142-00-6 C₂₀H₁₄ClN₃O 
• 1292833-61-4 C₂₁H₁₇N₃O₂ 
• 1593834-39-9 N-(2-phenyl-1H-benzo[d]imidazol-6-yl)quinolin-4-amine 

Relevant articles and documents

Cinnamide derived pyrimidine-benzimidazole hybrids as tubulin inhibitors: Synthesis, in silico and cell growth inhibition studies

An approach in modern medicinal chemistry to discover novel bioactive compounds is by mimicking diverse complementary pharmacophores. In extension of this strategy, a new class of piperazine-linked cinnamide derivatives of benzimidazole-pyrimidine hybrids have been designed and synthesized. Their in vitro cytotoxicity profiles were explored on selected human cancer cell lines. Specifically, structural comparison of target hybrids with tubulin-DAMA-colchicine and tubulin-nocodazole complexes has exposed a deep position of benzimidazole ring into the αT5 loop. All the synthesized compounds were demonstrated modest to interesting cytotoxicity against different cancer cell lines. The utmost cytotoxicity has shown with an amine linker of benzimidazole-pyrimidine series, with specificity toward A549 (lung cancer) cell line. The most potent compound in this series was 18i, which inhibited cancer cell growth at micromolar concentrations ranging 2.21–7.29 μM. Flow cytometry studies disclosed that 18i inhibited the cells in G2/M phase of cell cycle. The potent antitumor activity of 18i resulted from enhanced microtubule disruption at a similar level as nocodazole on β-tubulin antibody, explored using immunofluorescence staining. The most active compound 18i also inhibited tubulin polymerization with an IC50 of 5.72 ± 0.51 μM. In vitro biological analysis of 18i presented apoptosis induction on A549 cells with triggering of ROS generation and loss of mitochondrial membrane potential, resulting in DNA injury. In addition, 18i displayed impairment in cellular migration and inhibited the colony formation. Notably, the safety profile of most potent compound 18i was revealed by screening against normal human pulmonary epithelial cells (L132: IC50: 69.25 ± 5.95 μM). The detailed binding interactions of 18i with tubulin was investigated by employing molecular docking, superimposition and free energy analyses. Thus remarks made in this study established that pyrimidine-benzimidazole hybrids as a new class of tubulin polymerization inhibitors with significant anticancer activity.

6. 7 - dimethoxy - quinazoline - 4 - amine derivative, its preparation method and medical use

The invention discloses a 6, 7-dimethoxy-quinazoline-4-amine derivative. The 6, 7-dimethoxy-quinazoline-4-amine derivative is characterized by having the following formula as shown in the specification, wherein in the formula, R1 represents hydrogen, meth

Combinatorial synthesis of benzimidazole-azo-phenol derivatives as antifungal agents

A chemically diverse library of benzimidazole-azo-phenol derivatives was efficiently prepared and screened for their antifungal activities against five phytopathogenic fungi. Some compounds exhibited potent antifungal activities. As compared with a commercially available agricultural fungicide, hymexazol, especially compound V-5 showed the most promising broad-spectrum antifungal activities against five phytopathogenic fungi. The EC50 values of V-5 against F. graminearum, A. solani, V. mali, B. cinerea, and C. lunata were 0.09, 0.08, 0.06, 0.07, and 0.11 mol/mL, respectively.